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Abstract: Gadolinium-based carbon nanostructures are poised to make a significant impact 
as advanced contrast agents (CAs) for magnetic resonance imaging (MRI) in medicine. This 
paper reviews and forecasts gadonanotubes as synthons for the design of high-performance 
MRI CA probes with efficacies up to 100 times greater than current clinical CAs. This level of 
performance is vital for achieving the goal of cellular and molecular imaging with MRI. These 
new materials will be useful for in vivo MRI applications as circulating drug nanocapsules 
because of their low toxicities, extremely high relaxivities, and potential for cellular targeting 
and induced cell death by magnetic hyperthermia. 
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Introduction
Magnetic resonance imaging (MRI) is one of the most powerful and central techniques 
in diagnostic medicine and biomedical research (Mansfield 2004). Primarily, MRI 
non-invasively produces anatomical details for improved diagnosis of many diseases. 
Secondly, MRI also provides valuable information about the physiochemical state 
of tissues and blood flow. Thus, MRI is the method of choice for the diagnosis of 
many types of injuries and conditions, and it is not surprising that the use of MRI 
scanners is growing at an explosive rate. Today more than 22 000 MRI systems operate 
worldwide.
In clinical MRI, the nuclear magnetic resonance signal from water protons in living 
tissue are used to image organs and disease sites, such as tumors, in 3D. The intensity 
of this MR signal depends on three important intrinsic tissue factors: the proton density, 
the longitudinal relaxation time, T1, and the transverse relaxation time, T2. Thus, various 
mathematical techniques have been developed to highlight the differences in T1 or T2 
to obtain good contrast, ie, the difference in appearance of different tissues in an MR 
image. Otherwise, MR images would be fairly featureless since the amount of water 
does not vary significantly in the various tissues of in the body.
The development of MRI has also concurrently led to the development of 
chemical contrast-enhancement products called contrast agents (CAs). MRI CAs are 
used primarily to improve disease detection by increasing sensitivity and diagnostic 
confidence. There are several types of MRI CAs including extracellular fluid space 
(ECF) agents, extended-residence-intravascular agents (blood pool), and tissue 
(organ)-specific agents. Nearly all commercial CAs available today are ECF agents 
that distribute extracellularly and excrete exclusively via the kidney. Annually, 
approximately 60 million MRI procedures are performed worldwide; 30–35% of these 
procedures use MRI CAs. 
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CAs used in clinical MRI procedures operate by changing 
the proton nuclear spin relaxation times of water molecules 
in their vicinity, enhancing the detected MR signal in tissue 
(Lauffer 1987; Caravan et al 1999; Merbach et al 2001; 
Krause and Editors 2002). Thus, the most commonly used 
clinical CAs decrease T1 relaxation times (also referred to as 
spin-lattice relaxation ) of water protons in living tissue in the 
vicinity of the paramagnetic CA. All CAs are paramagnetic 
(with unpaired electrons) because paramagnetic CAs generate 
very large lattice fields (magnetic and nuclear environments 
with which the protons interact during T1 relaxation) in the 
immediate neighborhood of the CA, which greatly shorten the 
T1 of any water molecule that approaches the paramagnetic 
center. The term “relaxivity” (r1 for T1 relaxation) is the key 
determinant for evaluating the efficacy of any MRI CA. It 
is defined as the change in the relaxation rate of the water 
protons per molar concentration of the paramagnetic CA, 
and is expressed in units of mM
–1 sec
–1. 
The high-spin paramagnetic gadolinium (Gd
3+) metal ion 
is the most effective T1 relaxation agent. It has seven unpaired 
f-electrons, the greatest number of unpaired electrons 
exhibited by any atom or ion, a large magnetic moment 
(µ
2=63µB
2 where µB is the Bohr Magneton), and a highly 
symmetrical, slowly relaxing ground state (
8S-state) which 
produces strong oscillations near the 
1H Larmor frequency, 
and thus a strong T1 effect.
The aquated Gd
3+ ion is toxic, and therefore for medical 
use, its toxicity is usually sequestered by chelation with 
multidentate (linear and macrocyclic) ligands (Lauffer 
1987; Caravan et al 1999; Merbach et al 2001). Despite the 
impressive progress in the design and synthesis of Gd
3+ chelates 
for advanced CA applications, the resulting Gd
3+ complexes 
still possess limitations. For example, magnetic resonance 
angiography (MRA or blood-pool imaging) requires long 
retention times in the circulatory system and almost all Gd
3+ 
chelates are distributed extracellularly, with a low retention 
time in the blood pool (about 60 seconds), which makes 
them unsuitable for MRA. In addition, MRI of individual 
cells and their tissues (MR molecular imaging) requires that 
each Gd
3+ center possess an extremely large relaxivity in 
order to induce sufficient signal intensity. This requirement 
is due to the fact that the concentration of Gd
3+ centers that 
can be delivered or attached to the surface of a specific cell 
is largely limited to the nanomolar (nM) range by biological 
constraints (Nunn et al 1997). Gadolinium CAs in current 
clinical use with r1 ~4 mM
–1 s
–1 do not possess sufficiently 
large relaxivities for molecular imaging since r1 values greater 
than 100 mM
–1 s
–1 are generally required (Nunn et al 1997).
Gadonanotubes
Gd
3+-based carbon nanotube structures with their unique 
nanoscalar properties and superior performance as MRI CAs 
show promise for molecular imaging and other advanced 
applications. 
Single-walled carbon nanotubes (SWNTs) possess unique 
characteristics that make them desirable for biomedical 
applications (Martin and Kohli 2003). The ideal length for 
medical applications is uncertain, but ultra-short nanotubes 
(20–100 nm) or US-tubes (Gu et al 2002; Mackeyev et al   
2005) are probably best suited for cellular uptake, 
biocompatibility, and eventual elimination from the body. 
Additionally, the US-tube exterior surface provides a versatile 
scaffold for attachment of chemical groups for solubilizing 
or targeting purposes, while its interior space allows for 
encapsulation of atoms, ions, and even small molecules 
(Suenaga et al 2000; Monthioux 2002; Mackeyev et al 2005) 
whose cytotoxicity may be sequestered within the short 
carbon nanotube. Finally, medical-imaging agents derived 
from US-tubes hold promise for intracellular imaging, since 
carbon nanotubes have been shown to translocate into the 
interior of cells with minimal cytotoxicity (Dugan et al 1997; 
Wang et al 1999; Kam et al 2004; Lu et al 2004; Pantarotto 
et al 2004).
Recently, the first carbon nanotube-based CA called a 
“gadonanotube” (Figure 1 inset) was reported (Sitharaman et 
al 2005). This CA harnessed the ability of ultra-short single-
walled carbon nanotubes (US-tubes) to encase smaller ions or 
molecules within their framework by successfully loading and 
confining aquated Gd
3+
n-ion clusters within the nanoscalar 
confines of the US-tubes. Relaxometry and magnetometry 
Figure 1  Nuclear magnetic relaxation dispersion profile measured for Gd
3+
n@
US-tubes in a 1% sodium dodecylbenzene sulfonate solution (cGd = 0.044 mM; 
T = 37°C ) (◆). For comparative purposes, data for the commercially available 
CA, Magnevist
TM or (Gd[DTPA])
2– (▲), are also shown. inset: Depiction of 
a single US-tube loaded with hydrated Gd
3+ ions through sidewall defects 
created by cutting full-length nanotubes to produce US-tubes (not to scale and 
Cl
– anions and atoms attached to dangling C bonds not shown). international Journal of Nanomedicine 2006:1(3) 293
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studies revealed that these Gd
3+
n@US-tube species are linear 
superparamagnetic molecular magnets with MRI efficacies 
40–90 times larger than any current Gd
3+-based CA in 
clinical use. As such, gadonanotubes, with their embedded 
2–5 nm superparamagnetic Gd
3+
n-ion clusters, demonstrate 
potential as a radically new synthon for the development of 
high-performance MRI CAs.
Nuclear magnetic relaxation dispersion (NMRD) profiles   
can be of great help in determining the parameters influencing 
relaxivity, and they have played an important role in the devel-
opment of our understanding of proton relaxivity. NMRD 
profiles are proton-spin relaxivities measured as a function 
of magnetic field. The NMRD profile (B = 5 × 10
–4–9.4 T) 
for an aqueous solution of a Gd
3+
n@US-tube sample in 
1% SDBS (sodium dodecylbenzene sulfonate, a surfactant 
employed to suspend the highly lipophilic SWNTs in water) 
solution at 37°C, is presented in Figure 1. Also presented, for 
comparative purposes, are data for one of the commercially 
available MRI CAs, [Gd(DTPA)(H2O)]
2– (Magnevist
TM). For 
any magnetic field in Figure 1, the relaxivity for the Gd
3+
n@
US-tubes is remarkably larger than for the clinical CA. This 
is true at the standard MRI field strength (nearly 40 times 
larger) for clinical imaging of 20–60 MHz (170 mM
–1 s
–1 vs 
4.0 mM
–1 s
–1), but is even more pronounced (nearly 90 times 
larger) at very low fields such as 0.01 MHz (635 mM
–1 s
–1 vs 
7.0 mM
–1 s
–1).
In addition to the exceptionally large relaxivity values 
obtained for the gadonanotubes, the shape of the NMRD 
curve, as shown in Figure 1, is also considerably different 
from that reported so far for any other Gd
3+-based system. 
In particular, the relaxivities are continuously decreasing 
with increasing magnetic field at proton Larmor frequencies 
below 1 MHz, in contrast to the usual Gd
3+ CAs which present 
constant values at these low fields. Even more remarkable 
is the finding that at high magnetic fields (>60 MHz), the 
relaxivities remain practically constant, whereas a strong 
decrease is observed for the usual Gd
3+ CAs. 
The Solomon-Bloembergen-Morgan theory is unable to 
predict the observed shape of the NMRD profile and thus 
does not appear appropriate for gadonanotubes. Clearly, 
further investigations are needed in order to explain both 
the extremely large relaxivities and the magnetic-field 
dependency of the proton relaxivities for the gadonanotubes 
and possibly also other nanoscalar MRI CA materials. 
However, the data can be used to evaluate their potential 
efficacy as advanced MRI CAs.
To this end, we also recently conducted T1-weighted 
MRI phantom studies of the gadonanotubes at a 0.04 mM 
(Gd
3+). Additional vials containing the commercial contrast 
agent Magnevist
TM and deionized water solutions were also 
included in the imaging section as a reference for comparative 
purposes.
Representative T1-weighted MRI images of the vials are 
shown in Figure 2. At 0.04 mM (Gd
3+) the gadonanotubes 
showed extremely large signal enhancement compared to 
Magnevist
TM (ca. 100 times!) at the same concentration 
(Figures 2 and 3).
Figure 2  T1-weighted magnetic resonance imaging (Mri) phantoms of the 
Gd
3+
n@US-tubes solution at a 0.04 mM (Gd
3+). For comparative purposes, Mri 
phantoms of Magnevist
TM at a 0.04 mM (Gd
3+) and pure water are also shown. 
All data were collected using a 1.5T Philips Mri imager.
Figure 3  Magnitude signal-intensity curves for vials of Gd
3+
n@US-tubes ( ) 
and Magnevist
TM ( ) at the same Gd
3+ ion concentration of 0.04 mM, along with 
that of pure water (X). Note the substantially faster recovery time for the 
gadonanotubes probes when compared with the conventional CA.
Future applications
Universal Mr probes
The high relaxivity values for the gadonanotubes at all field 
strengths (low MR fields, current clinical MR fields and high 
MR fields) make these new gadonanotube materials suitable for 
use as universal MRI CAs. At the standard MRI field strength 
for clinical imaging in the 20–60 MHz range, their values 
are nearly 40 times larger than clinical CAs (170 mM
–1 s
–1   
vs 4.0 mM
–1 s
–1). The remarkably-high values at very low 
fields such as 0.01 MHz (635 mM
–1 s
–1 vs 7.0 mM
–1 s
–1) will 
especially benefit microtesla MRI imaging technologies 
(McDermott et al 2004). At high magnetic fields (>60 MHz), 
the ability of the gadonanotubes to maintain a nearly constant international Journal of Nanomedicine 2006:1(3) 294
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relaxivity is particularly important (Mansfield 2004) given 
the current tendency to develop MRI scanners of higher and 
higher fields; at these same fields, the contrast-enhancing 
effect of traditional CAs drops off. Currently, the most 
efficient T1 agents show a typical high-field relaxivity peak 
centered around 30–40 MHz which is characteristic of slow 
molecular rotation which can give maximum relaxivities 
of 40–50 Mm
–1 s
–1. Above this frequency, the relaxivity 
quickly vanishes to very small values for current MRI CAs. 
In this respect, gadonanotubes may represent a significant 
breakthrough in CA design for high-field imaging.
Cellular- and molecular-imaging probes
Molecular imaging is a new frontier for diagnostic medicine. 
It aims to strengthen diagnostic accuracy of existing image 
modalities and their interpretation by probing unique 
biological signatures or sub-cellular processes that are at the 
cause of disease. The gadonanotube materials considered 
here would seem to hold exceptional promise for molecular 
imaging for the following reasons: 
a)  Their external surfaces can be used as a scaffold to 
attach a wide variety of agents. These agents can be water-
solubilizing groups, biocompatible coverings, and even 
antibodies or peptides for active targeting of a specific cell 
type of interest, such as malignant cells.
b)  Biological constraints limit targeted receptor sites on 
cell surfaces to very low concentrations (nM–pM/g of tissue) 
(Nunn et al 1997). The exceptionally large T1 relaxivities of 
the gadonanotubes (Figure 1) could provide sufficient signal-
to-noise to image cell-surface receptor sites in the nanomolar 
range. For example, for a clinical CA with r1 = 4.0 mM
–1 s
–1 at 
clinical field strengths, the minimum detectable concentration 
of Gd
3+ is 10
–4 M (Nunn et al 1997). The increase in relaxivity 
provided by the gadonanotube changes this minimum 
concentration to approximately 2 x 10
–9 M.
c)  Recently, SWNTs have been shown to translocate 
into the interior of cells with minimal cytotoxicity (Dugan 
et al 1997; Wang et al 1999; Kam et al 2004; Lu et al 
2004; Pantarotto et al 2004). Thus, CA probes derived 
from these materials could also accumulate within targeted 
cells to further boost MRI signal strength. For example, we 
estimated that a (10 nm x 100 nm) gadonanotube probe, with 
r1 = 170 mM
–1 s
–1 per Gd
3+ at clinical fields, contains about 100 
Gd
3+ ions. This should give an effective r1 = 17 000 mM
–1 s
–1 
per probe. (Here we have estimated the T1 relaxation rate per 
nanoprobe, since the relaxation effect will be due to the entire 
densely-packed nanoprobe rather than individual Gd centers.) 
If just 1000 such probes were to accumulate within a single 
cell, the relaxivity of the cell would be 17 000 000 mM
–1 s
–1 
(!) which should easily permit cellular imaging. The use of 
progenitor and stem cells in humans for cellular therapies will 
require a technique that can accurately monitor their fate and 
delivery noninvasively and repeatedly. MRI is ideally suited 
to study the migration and tissue integration of magnetically 
labeled adult stem cells. Early detection of cancer cells would 
be another very desirable application of such a intracellular 
molecular-imaging capability. 
Guided-therapy probes
The superparamagnetic gadonanotubes also show promise for 
the development of the first Gd
3+-based MRI image-guided 
therapeutic agent that can used for targeted magnetic-field-
induced hyperthermia. While heating a cancer cell or tumor 
to the point of therapeutic destruction can be accomplished by 
several methods (Moroz et al 2002), the least intrusive is the 
use of a magnetically mediated agent. Although any magnetic 
material can be magnetically induced to generate heat, single 
domain particles (superparamagnetic materials like the 
gadonanotubes) are preferred because they can produce far 
more heat at safer (lower) magnetic fields compared with 
ferromagnetic materials (Moroz et al 2002). The limitation of 
hyperthermia for human treatment is the failure to generate 
appreciable heat at safe magnetic fields. However, recent 
results with ultra-small iron oxide particles (USPIOs) have 
shown promise for the first human trials (Moroz et al 2002). 
The gadonanotubes may make ideal MRI-delivery capsules 
for cancer imaging–therapy by magnetic hyperthermia due 
to their nanoscalar size, superparamagnetism, external 
derivatization potential, and intrinsically intracellular 
nature. Furthermore, non-spherical particles such as the 
gadonanotubes are yet to tested as hyperthermia agents, and 
it is possible that their unique rod-shaped geometry (aspect 
ratio of 100:1) may augment performance through non-axial 
Brownian relaxation (Rosensweig 2002). 
Acknowledgment
The original research reviewed and discussed in this chapter 
was supported by the NIH (Grant 1-R01-EB000703) and 
the Robert A Welch Foundation (Grant C-0627). We thank 
Professor Andre Merbach’s group at the Ecole Polytechnique 
Fédérale de Lausanne, EPFL-BCH; CH-1015 Lausanne, 
Switzerland for the NMRD data as well as Dr Raja 
Muthupillai and Dr Scott D Flamm for the MRI phantom 
imaging. SB acknowledges support by the J. Evans Attwell-
Welch postdoctoral training fellowship.international Journal of Nanomedicine 2006:1(3) 295
Gadonanotunes as Mri contrast agents
References
Caravan P, Elllison JJ, McMurry TJ, et al. 1999. Gadolinium(III) chelates 
as MRI contrast agents: structure, dynamics, and applications. Chem 
Rev, 99:2293–352.
Dugan LL, Turetsky DM, Du C, et al. 1997. Carboxyfullerenes as 
neuroprotective antioxidants. Proc Natl Acad Sci U S A, 94:9434–9.
Gu ZH, Peng H, Hauge RH, et al. 2002. Cutting single-wall carbon nanotubes 
through fluorination. Nano Lett, 2:1009–13.
Kam NWS, Jessop TC, Paul AW, et al. 2004. Nanotube molecular 
transporters: internalization of carbon nanotube-protein conjugates 
into mammalian cells. J Am Chem Soc, 126:6850–1.
Krause W and Editors 2002. Topics in current chemistry 221. Contrast agents 
I: magnetic resonance imaging. Berlin: Springer-Verlag.
Lauffer RB. 1987. Paramagnetic metal complexes as water proton relaxation 
agents for NMR imaging: Theory and design. Chem Rev, 87:901–27.
Lu Q, Moore JM, Huang G, et al. 2004. RNA polymer translocation with 
single-walled carbon nanotubes. Nano Lett, 4:2473–7.
McDermott R, Lee S, Ten-Haken B, et al. 2004. Microtesla MRI with a 
superconducting quantum interference device. Proc Natl Acad Sci U 
S A, 101:7857––61.
Mackeyev YA, Marks JW, Rosenblum MG, et al. 2005. Stable containment 
of radionuclides on the nanoscale by cut single-wall carbon nanotubes. 
J Phys Chem B, 109:5482–4.
Mansfield P. 2004. Snapshot magnetic resonance imaging. Angew Chem 
Int Ed Engl, 43: 5456–64.
Martin CR and Kohli P 2003. The emerging field of nanotube biotechnology. 
Nat Rev Drug Discov, 2:29–37.
Merbach AE, Toth E. 2001. The chemistry of contrast agents in medical 
magnetic resonance imaging. Chichester: John Wiley & Sons,.
Monthioux M. 2002. Filling single-wall carbon nanotubes. Carbon, 
40:1809–23.
Moroz P, Jones SK, Gray BN. 2002. Magnetically mediated hyperthermia: 
current status and future direction. Intl J Hyperthermia, 18:267–84.
Nunn AD, Linder KE, Tweedle MF. 1997. Can receptors be imaged with 
MRI agents? Quart J Nucl Med, 41:155–62.
Pantarotto D, Briand JP, Prato M. et al. 2004. Translocation of bioactive 
peptides across cell membranes by carbon nanotubes. Chem Commun, 
1:16–17.
Rosensweig RE. 2002. Heating magnetic fluid with alternating magnetic 
field. Journal of Magnetism and Magnetic Materials, 252:370–4.
Sitharaman B, Kissell KR, Hartman KB, et al. 2005. Superparamagnetic 
gadonanotubes are high-performance MRI contrast agents. Chem 
Commun, 3:3915–17.
Suenaga K, Tence M, Mory C, et al. 2000. Element-selective single atom 
imaging. Science, 290(5500):2280–1.
Wang CI., Tai LA, Lee DD, et al. 1999. [TITLE?] J Med Chem, 42:4614.